Your search found 4 Results
Bulletin of the World Health Organization. 2016 Nov; 94(11):787-787A.Add to my documents.
Current Opinion In Infectious Diseases. 2008 Dec; 21(6):653-8.PURPOSE OF REVIEW: As antiretroviral therapy scale-up proceeds in developing countries, simple and inexpensive procedures are required to monitor the prevalence and transmission of drug-resistant HIV strains to ensure optimal use of antiviral therapy. This article reviews new surveillance methods and practices used to monitor drug resistance in the developing world. RECENT FINDINGS: Several recently published studies report the successful development of methods using dried blood spots, collected on filter paper, for HIV drug resistance genotyping tests. In concert to antiretroviral therapy rollout, the WHO has developed a laboratory network and sought to implement surveillance of transmitted drug resistance in developing countries. A small number of developing world prevalence studies have thus far been published using dried blood spots. These studies reveal low rates of transmitted drug resistance. Other studies indicate that the use of dried blood spots for HIV drug resistance surveillance may possibly lead to overestimates. SUMMARY: The use of dried blood spots as a method of specimen collection and storage is simple, inexpensive and is an appropriate technique for the surveillance of transmitted HIV drug resistance.
Reaching regional consensus on improved behavioural and serosurveillance for HIV: report from a regional conference in East Africa.
Geneva, Switzerland, Joint United Nations Programme on HIV / AIDS [UNAIDS], 1998. 12 p. (UNAIDS Best Practice Collection. Key Material; UNAIDS/98.9)This report documents a regional workshop on surveillance systems for HIV held in Nairobi, Kenya, on 10.13 February 1997. The UNAIDS-funded workshop gathered government epidemiologists, AIDS programme managers, and social scientists from Kenya, Malawi, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe as well as specialists from UNAIDS and other partner institutions. The group aimed to present current data and to work together to suggest practical guidelines for improving HIV surveillance systems in a maturing epidemic. (excerpt)
Interim patient monitoring guidelines for HIV care and ART. Based on the WHO HIV Patient ART Monitoring Meeting, held at WHO / HQ, Geneva, Switzerland, from 29-31 March 2004. (March 2005 update of 6th August 2004 draft).
Geneva, Switzerland, WHO, 2005 Mar. 191 p.These guidelines have been provided by the World Health Organization (WHO) and other international partners in order to: 1. Facilitate national stakeholder consensus on a minimum, standardized set of data elements to be included in patient monitoring tools; 2. Aid in the development of an effective national HIV care/ART patient monitoring system; 3. Enable the rapid scale-up of effective chronic HIV care, ART and prevention; and 4. Contribute to effective programme monitoring and global reporting and planning through the measurement of district-, national- and international-level indicators. (excerpt)